{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:51:23Z","timestamp":1774482683116,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T32DK00706"],"award-info":[{"award-number":["T32DK00706"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK123392"],"award-info":[{"award-number":["K23DK123392"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["23CDA1053072"],"award-info":[{"award-number":["23CDA1053072"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL144941"],"award-info":[{"award-number":["R01HL144941"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008871","name":"Juvenile Diabetes Research Foundation United States of America","doi-asserted-by":"publisher","award":["5-ECR-2020-950-A-N"],"award-info":[{"award-number":["5-ECR-2020-950-A-N"]}],"id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Appleby Fund"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002243"],"award-info":[{"award-number":["UL1 TR002243"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Individuals with type 1 diabetes mellitus (T1DM) must deliver insulin into the peripheral circulation rather than more physiologically into the hepatic portal circulation, leading to a chronic state of underinsulinization in the liver. Previous research suggests that decreased hepatic insulin perturbs the growth hormone-IGF-1 system in these patients. We tested whether short-term carbohydrate restriction, by lowering exogenous insulin requirements and exacerbating hepatic underinsulinization, modifies IGF axis hormones, binding proteins, and vascular function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a secondary analysis of plasma samples collected during a single-blind crossover study of twelve adults with T1DM using automated insulin delivery. In random order, the participants consumed a one-week reduced carbohydrate diet (RCD) and an isocaloric standard carbohydrate diet (SCD), each followed by a study visit. We measured total and free IGF-1 and IGF-binding proteins (IGFBP-1, IGFBP-2, and IGFBP-3) after overnight fasting and during the final 30\u00a0min of a hyperinsulinemic-euglycemic clamp. We also measured endothelial function using brachial artery flow-mediated dilation (FMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The RCD lowered the total daily insulin dose versus SCD (16% during the week and 24% in the 24\u00a0h before testing), with similar glucose levels across diets. Compared with SCD, RCD reduced total IGF-1 and IGFBP-3 and increased IGFBP-1 and IGFBP-2 at baseline. These patterns also persisted during insulin-stimulated conditions. Free IGF-1 was more variable and did not differ significantly between diets. Despite clear shifts in the IGF axis, FMD did not differ between diets and did not correlate with IGF axis markers after either intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In adults with T1DM studied under nearly matched glycemia, one week of carbohydrate reduction lowered insulin requirements and shifted the IGF axis in a pattern akin to reduced portal insulin exposure, without detectable changes in conduit artery endothelial function. These findings identify the IGF axis as a sensitive physiologic readout of insulin exposure. Longer-term studies are needed to determine whether sustained changes in the IGF axis impact vascular biology or cardiometabolic risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT04118374.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40842-026-00276-6","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:02:27Z","timestamp":1774479747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A one-week reduced-carbohydrate diet lowers insulin requirements and shifts the IGF axis with no detectable short-term change in endothelial function in a randomized, crossover trial of adults with type 1 diabetes"],"prefix":"10.1186","volume":"12","author":[{"given":"M. Naweed","family":"Akbar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Jordan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivaprakasam","family":"Chinnarasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendi","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Zuofei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget","family":"Litts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren M.","family":"LeStourgeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Mabood","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annet","family":"Kirabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin M.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"21","key":"276_CR1","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","volume":"371","author":"M Lind","year":"2014","unstructured":"Lind M, Svensson AM, Kosiborod M, Gudbj\u00f6rnsdottir S, Pivodic A, Wedel H, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371(21):1972\u201382.","journal-title":"N Engl J Med"},{"issue":"3","key":"276_CR2","first-page":"872","volume":"79","author":"K Brismar","year":"1994","unstructured":"Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab. 1994;79(3):872\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"276_CR3","doi-asserted-by":"crossref","unstructured":"Lewitt MS, Boyd GW. Insulin-like growth factor-binding protein-1 (IGFBP-1) as a biomarker of cardiovascular disease. Biomolecules. 2024;14(11).","DOI":"10.3390\/biom14111475"},{"key":"276_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ghir.2017.12.005","volume":"38","author":"B Nambam","year":"2018","unstructured":"Nambam B, Schatz D. Growth hormone and insulin-like growth factor-I axis in type 1 diabetes. Growth Horm IGF Res. 2018;38:49\u201352.","journal-title":"Growth Horm IGF Res"},{"issue":"4","key":"276_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1530\/EJE-14-0258","volume":"171","author":"Z Ma","year":"2014","unstructured":"Ma Z, Christiansen JS, Laursen T, Lauritzen T, Frystyk J. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes. Eur J Endocrinol. 2014;171(4):471\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"276_CR6","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.1210\/en.2010-0672","volume":"151","author":"PM Yamada","year":"2010","unstructured":"Yamada PM, Mehta HH, Hwang D, Roos KP, Hevener AL, Lee KW. Evidence of a role for insulin-like growth factor binding protein (IGFBP)-3 in metabolic regulation. Endocrinology. 2010;151(12):5741\u201350.","journal-title":"Endocrinology"},{"issue":"3","key":"276_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jcmgh.2020.06.006","volume":"10","author":"M Mar\u00ed","year":"2020","unstructured":"Mar\u00ed M. IGFBP-3: so much more than an IGF1\/2 binding protein. Cell Mol Gastroenterol Hepatol. 2020;10(3):643\u20134.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"276_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ghir.2019.01.002","volume":"45","author":"Y Higashi","year":"2019","unstructured":"Higashi Y, Gautam S, Delafontaine P, Sukhanov S. IGF-1 and cardiovascular disease. Growth Horm IGF Res. 2019;45:6\u201316.","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"276_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/cen.12296","volume":"81","author":"CA Hedman","year":"2014","unstructured":"Hedman CA, Frystyk J, Lindstr\u00f6m T, Oskarsson P, Arnqvist HJ. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion. Clin Endocrinol (Oxf). 2014;81(1):58\u201362.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"276_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0168-8227(94)90155-4","volume":"25","author":"PI Shishko","year":"1994","unstructured":"Shishko PI, Dreval AV, Abugova IA, Zajarny IU, Goncharov VC. Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res Clin Pract. 1994;25(1):1\u201312.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"276_CR11","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1210\/jc.2016-1473","volume":"101","author":"PR van Dijk","year":"2016","unstructured":"van Dijk PR, Logtenberg SJ, Chisalita SI, Hedman CA, Groenier KH, Gans RO, et al. Different effects of intraperitoneal and subcutaneous insulin administration on the GH-IGF-1 axis in type 1 diabetes. J Clin Endocrinol Metab. 2016;101(6):2493\u2013501.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"276_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2265.2000.00922.x","volume":"52","author":"JA Janssen","year":"2000","unstructured":"Janssen JA, Lamberts SW. Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol (Oxf). 2000;52(1):1\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"276_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2337\/db11-0963","volume":"61","author":"A Rajwani","year":"2012","unstructured":"Rajwani A, Ezzat V, Smith J, Yuldasheva NY, Duncan ER, Gage M, et al. Increasing Circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis. Diabetes. 2012;61(4):915\u201324.","journal-title":"Diabetes"},{"issue":"1","key":"276_CR14","doi-asserted-by":"publisher","first-page":"T139","DOI":"10.1530\/JME-18-0016","volume":"61","author":"DR Clemmons","year":"2018","unstructured":"Clemmons DR. Role of IGF-binding proteins in regulating IGF responses to changes in metabolism. J Mol Endocrinol. 2018;61(1):T139\u201369.","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"276_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1210\/jc.2003-030967","volume":"89","author":"GA Laughlin","year":"2004","unstructured":"Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the rancho Bernardo study. J Clin Endocrinol Metab. 2004;89(1):114\u201320.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"276_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3803\/EnM.2024.101","volume":"39","author":"EC Nijenhuis-Noort","year":"2024","unstructured":"Nijenhuis-Noort EC, Berk KA, Neggers S, Lely AJV. The fascinating interplay between growth Hormone, insulin-Like growth Factor-1, and insulin. Endocrinol Metab (Seoul). 2024;39(1):83\u20139.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"5","key":"276_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2337\/dbi19-0026","volume":"69","author":"JM Gregory","year":"2020","unstructured":"Gregory JM, Cherrington AD, Moore DJ. The peripheral peril: injected insulin induces insulin insensitivity in type 1 diabetes. Diabetes. 2020;69(5):837\u201347.","journal-title":"Diabetes"},{"issue":"10","key":"276_CR18","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.2337\/db15-0071","volume":"64","author":"JM Gregory","year":"2015","unstructured":"Gregory JM, Kraft G, Scott MF, Neal DW, Farmer B, Smith MS, et al. Insulin delivery into the peripheral circulation: A key contributor to hypoglycemia in type 1 diabetes. Diabetes. 2015;64(10):3439\u201351.","journal-title":"Diabetes"},{"issue":"10","key":"276_CR19","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1111\/dom.13808","volume":"21","author":"JM Gregory","year":"2019","unstructured":"Gregory JM, Kraft G, Scott MF, Neal DW, Farmer B, Smith MS, et al. Peripherally delivered Hepatopreferential insulin analog insulin-406 mimics the hypoglycaemia-sparing effect of portal vein human insulin infusion in dogs. Diabetes Obes Metab. 2019;21(10):2294\u2013304.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"276_CR20","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.2337\/db19-0324","volume":"68","author":"JM Gregory","year":"2019","unstructured":"Gregory JM, Smith TJ, Slaughter JC, Mason HR, Hughey CC, Smith MS, et al. Iatrogenic Hyperinsulinemia, not Hyperglycemia, drives insulin resistance in type 1 diabetes as revealed by comparison with GCK-MODY (MODY2). Diabetes. 2019;68(8):1565\u201376.","journal-title":"Diabetes"},{"issue":"3","key":"276_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1046\/j.1365-2265.1999.00775.x","volume":"51","author":"E Fernqvist-Forbes","year":"1999","unstructured":"Fernqvist-Forbes E, Ekberg K, Lindgren BF, Brismar K. Splanchnic exchange of insulin-like growth factor binding protein-1 (IGFBP-1), IGF-I and acid-labile subunit (ALS) during normo- and hyper-insulinaemia in healthy subjects. Clin Endocrinol. 1999;51(3):327\u201332.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"276_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-025-02658-z","volume":"24","author":"JM Gregory","year":"2025","unstructured":"Gregory JM, Smith TJ, Duffus SH, Brooks D, Akbar MN, Huntley MA, et al. A one-week reduced-carbohydrate diet to mitigate iatrogenic peripheral hyperinsulinemia does not improve insulin sensitivity or endothelial function in a randomized, crossover trial in patients with type 1 diabetes. Cardiovasc Diabetol. 2025;24(1):107.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"276_CR23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1158\/1055-9965.EPI-08-0781","volume":"18","author":"FL Crowe","year":"2009","unstructured":"Crowe FL, Key TJ, Allen NE, Appleby PN, Roddam A, Overvad K, et al. The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1333\u201340.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"276_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s41043-024-00698-x","volume":"43","author":"ZS Sangsefidi","year":"2024","unstructured":"Sangsefidi ZS, Soltani S, Meshkini F, Torabynasab K, Zeraattalab-Motlagh S, Razmpoosh E, et al. Effectiveness of low-fat diet on the levels of insulin-like growth factor-1 and insulin-like growth factor binding proteins: a systematic review and meta-analysis of randomized controlled clinical trials. J Health Popul Nutr. 2024;43(1):201.","journal-title":"J Health Popul Nutr"},{"issue":"6","key":"276_CR25","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1007\/s00394-021-02518-y","volume":"60","author":"R Sch\u00fcler","year":"2021","unstructured":"Sch\u00fcler R, Markova M, Osterhoff MA, Arafat A, Pivovarova O, Machann J, et al. Similar dietary regulation of IGF-1- and IGF-binding proteins by animal and plant protein in subjects with type 2 diabetes. Eur J Nutr. 2021;60(6):3499\u2013504.","journal-title":"Eur J Nutr"},{"key":"276_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000360571","volume":"43","author":"Y Higashi","year":"2014","unstructured":"Higashi Y, Quevedo HC, Tiwari S, Sukhanov S, Shai SY, Anwar A, Delafontaine P. Interaction between insulin-like growth factor-1 and atherosclerosis and vascular aging. Front Horm Res. 2014;43:107\u201324.","journal-title":"Front Horm Res"},{"key":"276_CR27","doi-asserted-by":"crossref","unstructured":"Meyer NMT, Kabisch S, Dambeck U, Honsek C, Kemper M, Gerbracht C, et al. IGF-1 and IGFBP-1 as possible predictors of response to lifestyle intervention-results from randomized controlled trials. Int J Mol Sci. 2024;25(12).","DOI":"10.3390\/ijms25126400"},{"key":"276_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1472-6823-14-35","volume":"14","author":"Z Ma","year":"2014","unstructured":"Ma Z, Christiansen JS, Laursen T, Wu C, Lauritzen T, Parkner T, Frystyk J. Effects of human insulin and insulin Aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes. BMC Endocr Disord. 2014;14:35.","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"276_CR29","first-page":"753","volume":"121","author":"HP Guler","year":"1989","unstructured":"Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh). 1989;121(6):753\u20138.","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"5","key":"276_CR30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1161\/hc0502.103333","volume":"105","author":"G Arcaro","year":"2002","unstructured":"Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, Bonadonna RC. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002;105(5):576\u201382.","journal-title":"Circulation"},{"issue":"1","key":"276_CR31","doi-asserted-by":"publisher","first-page":"H76","DOI":"10.1152\/ajpheart.00539.2003","volume":"286","author":"U Campia","year":"2004","unstructured":"Campia U, Sullivan G, Bryant MB, Waclawiw MA, Quon MJ, Panza JA. Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile. Am J Physiol Heart Circ Physiol. 2004;286(1):H76\u201382.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"276_CR32","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00424-013-1218-z","volume":"465","author":"VK Gatenby","year":"2013","unstructured":"Gatenby VK, Imrie H, Kearney M. The IGF-1 receptor and regulation of nitric oxide bioavailability and insulin signalling in the endothelium. Pflugers Arch. 2013;465(8):1065\u201374.","journal-title":"Pflugers Arch"},{"issue":"1\u20132","key":"276_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mce.2004.10.003","volume":"229","author":"MD Nitert","year":"2005","unstructured":"Nitert MD, Chisalita SI, Olsson K, Bornfeldt KE, Arnqvist HJ. IGF-I\/insulin hybrid receptors in human endothelial cells. Mol Cell Endocrinol. 2005;229(1\u20132):31\u20137.","journal-title":"Mol Cell Endocrinol"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00276-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-026-00276-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00276-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:02:30Z","timestamp":1774479750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-026-00276-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["276"],"URL":"https:\/\/doi.org\/10.1186\/s40842-026-00276-6","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Vanderbilt University Institutional Review Board and registered at ClinicalTrials.gov (NCT04118374).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.M.G. has received consulting fees from vTV therapeutics, DRI Capital Inc., Beckman Coulter Inc., and Sanofi; reimbursement for serving on scientific advisory committees for vTV therapeutics and Sanofi; honoraria for educational events with MJH Life Sciences; and payments for participation on a clinical events committee for Medtronic.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}